<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002475</url>
  </required_header>
  <id_info>
    <org_study_id>SVMC-ONC-222</org_study_id>
    <secondary_id>CDR0000076913</secondary_id>
    <secondary_id>NCI-V91-0075</secondary_id>
    <nct_id>NCT00002475</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer</brief_title>
  <official_title>A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Vincent Medical Center - Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make&#xD;
      the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine&#xD;
      therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor&#xD;
      cell vaccine in treating patients who have metastatic cancer or cancer at high risk of&#xD;
      recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and clinical effects of autologous or allogeneic active-specific&#xD;
           intralymphatic immunotherapy with a vaccine containing interferon alfa or interferon&#xD;
           gamma-treated tumor cells followed by sargramostim (GM-CSF) in patients with advanced&#xD;
           cancer.&#xD;
&#xD;
      OUTLINE: This is a pilot study. Patients are stratified by tumor type.&#xD;
&#xD;
      Tumor tissue is removed from the patient and incubated with interferon alfa or interferon&#xD;
      gamma for 72-96 hours. (If autologous tumor cells are not available, an allogeneic vaccine is&#xD;
      prepared.) Harvested activated cells are irradiated immediately prior to use.&#xD;
&#xD;
      Patients receive cyclophosphamide IV. 48-72 hours after cyclophosphamide administration,&#xD;
      patients receive tumor cell vaccine intradermally. Patients also receive sargramostim&#xD;
      (GM-CSF) subcutaneously prior to vaccine administration and once daily for the next 8 days.&#xD;
      Treatment repeats every 2 weeks for 3 courses in the absence of unacceptable toxicity.&#xD;
      Patients with responding or stable disease after completion of course 3 may receive&#xD;
      additional courses.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1991</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response (patients with evaluable disease)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (patients with evaluable disease)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival (patients with evaluable disease)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recurrence (patients without evaluable disease)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival (patients without evaluable disease)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon gamma</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cancer not amenable to cure or long-term control by surgery,&#xD;
             radiotherapy, chemotherapy, or hormonal manipulations, including the following tumor&#xD;
             types:&#xD;
&#xD;
               -  Colon cancer&#xD;
&#xD;
               -  Lung cancer&#xD;
&#xD;
               -  Renal cancer&#xD;
&#xD;
               -  Breast cancer&#xD;
&#xD;
               -  Pancreatic cancer&#xD;
&#xD;
          -  Metastatic disease or subclinical disease at high risk of recurrence&#xD;
&#xD;
          -  No brain metastases unresponsive to irradiation or surgery&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior or concurrent significant cardiovascular disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No prior or concurrent pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior or concurrent autoimmune disease&#xD;
&#xD;
          -  No other prior or concurrent major medical illness&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No clinical evidence of AIDS&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent chronic steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Wiseman, MD, FACP</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Medical Center - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057-1901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wiseman C, Presant C, Rao R, Smith J. Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Ann N Y Acad Sci. 1993 Aug 12;690:388-91. doi: 10.1111/j.1749-6632.1993.tb44040.x. No abstract available.</citation>
    <PMID>8368765</PMID>
  </results_reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Charles L. Wiseman</name_title>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

